Results 21 to 30 of about 59,855 (258)

VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia

open access: yesIssues in Mental Health Nursing, 2021
Psychiatric nurses are at the forefront of optimizing psychiatric care, including educating patients and caregivers on the risks of antipsychotic-induced movement disorders such as tardive dyskinesia (TD).
Barbara Warren   +2 more
semanticscholar   +1 more source

Treatment of tardive dyskinesias with vitamin E: A case series

open access: yesEuropean Psychiatry, 2023
Introduction Tardive dyskinesia is usually persistent, irreversible involuntary movement of the tongue, lips, face, trunk and extremities in patients taking long-term dopaminergic antagonist drugs.
B. Senol   +3 more
doaj   +1 more source

Tardive Dyskinesia and Treatment Approaches [PDF]

open access: yesPsikiyatride Güncel Yaklaşımlar, 2018
Tardive dyskinesia is an iatrogenic movement disorder with an incompletely determined etiology. Involuntary movements can effect oral, lingual, facial, corporal muscles and can be permanent. Tardive dyskinesia is one of the most important side effects of
Mehmet Emin Demirkol   +3 more
doaj   +1 more source

Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? [PDF]

open access: bronzeInternational journal of clinical practice, 2017
The objective of this systematic review was to describe the efficacy, tolerability, and safety of valbenazine for the treatment of tardive dyskinesia (TD).
Leslie Citrome
openalex   +2 more sources

An Update on Tardive Dyskinesia: From Phenomenology to Treatment

open access: greenTremor and Other Hyperkinetic Movements, 2013
Tardive dyskinesia (TD), characterized by oro-buccal-lingual stereotypy, can manifest in the form of akathisia, dystonia, tics, tremor, chorea, or as a combination of different types of abnormal movements.
Olga Waln, Joseph Jankovic
openalex   +3 more sources

Metoclopramide in Gastroparesis: Its Mechanism of Action and Safety Profile

open access: yesGastrointestinal Disorders, 2023
Metoclopramide has been the cornerstone of gastroparesis management for the past 40 years as it is the only FDA-approved medication for gastroparesis. Other medications such as erythromycin and domperidone have been used off-label with variable efficacy.
M Ammar Kalas   +4 more
doaj   +1 more source

CLINICAL AND SOCIAL RISK FACTORS OF TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA DURING ANTIPSYCHOTIC TREATMENT

open access: yesБюллетень сибирской медицины, 2015
The purpose of the present work was to study the clinical features and risk factors of tardive dyskinesia among     the     schizophrenia     patients     who     durably     receive     the     antipsychotic     therapy.
Ye. G. Kornetova   +4 more
doaj   +1 more source

Tardive dyskinesia

open access: yesGeriatric Nursing, 1982
Tardive dyskinesia is now widely recognised as a neurological disorder associated with the administration of antipsychotic drugs. Prevalence is higher among the elderly. The cause is unknown but the hypothesis of hypersensitivity of post-synaptic dopamine receptors is currently generally accepted.
V A, Portnoi, J E, Johnson
openaire   +5 more sources

Home - About - Disclaimer - Privacy